Hematocrit

BioIVT Announces Expansive Fresh Leukopak Capability in Europe

Retrieved on: 
Thursday, February 22, 2024

WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks. Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.

Key Points: 
  • WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.
  • Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.
  • To support this growing demand, BioIVT now has the ability to provide researchers across Europe with high quality, fresh starting material within 24 hours of collection.
  • "Access to fresh leukopaks enables clients with the crucial elements needed for effective and efficient therapeutic development and approval," said Dr. Parijat Jain, Vice President, CGT at BioIVT.

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
Tuesday, February 6, 2024

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Alio Announces Expansion of Operations in GCC Market to the UAE Through Partnership with GulfDrug

Retrieved on: 
Monday, January 8, 2024

BROOMFIELD, Colo., Jan. 8, 2024 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with GulfDrug, one of the top medical suppliers in the United Arab Emirates (UAE). Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE. GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment. GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Key Points: 
  • announces its strategic partnership with GulfDrug , one of the top medical suppliers in the United Arab Emirates (UAE).
  • Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE.
  • GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment.
  • GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Hematology Diagnostics Global Strategic Research Report 2023: Market to Reach $11.9 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023

The "Hematology Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hematology Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Hematology Diagnostics estimated at US$7.6 Billion in the year 2022, is projected to reach a revised size of US$11.9 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2022-2030.
  • It also includes an assessment of the market for consumables and instruments used in hematology diagnostics.
  • The Hematology Diagnostics market in the U.S. is estimated at US$2.1 Billion in the year 2022.

BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device

Retrieved on: 
Thursday, December 7, 2023

FRANKLIN LAKES, N.J., Dec. 7, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.

Key Points: 
  • It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies.
  • The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing.
  • BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.
  • We believe the BD MiniDraw™ Collection System is potentially a game-changing innovation that combines convenience and better patient experience with lab-quality results."

Alio Officially Enters GCC Market Through Partnership with Al Redwan

Retrieved on: 
Tuesday, December 5, 2023

BROOMFIELD, Colo., Dec. 5, 2023 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with Al Redwan Medical Services Company, a leader in dialysis and medical lab trading and medical services in the Gulf region. Alio, already commercially available in the United States, has expanded its global presence to the Kingdom of Saudi Arabia to reach a greater number of kidney patients in need.

Key Points: 
  • The Alio Platform dramatically improves the technology solutions available to clinicians by delivering actionable, clinical-grade metrics and notifications at key intervention points.
  • Alio's partnership with Al Redwan allows Alio to manage the more than 3,000 End-Stage Kidney Disease (ESKD) patients for whom Al Redwan directly provides dialysis.
  • Beyond the patients already under Al Redwan's care, the partnership will also enable and facilitate the distribution of Alio products to other hospitals, providers, and partners in the region, including Diaverum.
  • Unfortunately, the technology available to date has only catered to one or two of their conditions," said Mr. Yousef Al Redwan, CEO of Al Redwan Medical Services.

Alio's Remote Monitoring Platform Now Notifies Clinicians of Atypical Acoustic Data from Patients with Vascular Access

Retrieved on: 
Thursday, September 28, 2023

BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site. While the platform was FDA-cleared in March of this year to function as a stethoscope and collect auscultation data, this new notification draws the clinician's attention to a specific set of recordings which indicate the absence of typical sound data. The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope. Rather than manually taking readings, the Alio SmartPatch automatically takes readings and makes it possible for clinicians to monitor a patient's vascular access remotely with no action required from the patient. 

Key Points: 
  • BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site.
  • The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope.
  • Sound data from the vascular access is essential in managing an ESKD patient's condition and preserving a critical lifeline.
  • The Alio Remote Monitoring Platform makes it possible for clinicians to receive timely notifications regarding their patients.

Alio Secures Commercial Customer, Premier Dialysis, Further Extending its Reach Within the Kidney Disease Landscape

Retrieved on: 
Thursday, September 14, 2023

BROOMFIELD, Colo., Sept. 14, 2023 /PRNewswire/ -- Today, Alio, Inc. announces official launch with commercial customer, Premier Dialysis. The two organizations are mutually aligned on helping dialysis patients improve their quality of life through better management of their condition and by empowering them with the tools necessary to do so. Both organizations also believe dialysis patients have been forced to live with the status quo for far too long and lacked access to new innovative approaches to managing their condition.

Key Points: 
  • Premier Dialysis is a dialysis solution company focused on improving quality of life through their QPLD protocol which is a dextrose-free, cycler-free dialysis methodology.
  • Premier Dialysis' trademarked approach helps patients avoid more aggressive forms of dialysis treatment and helps maintain residual kidney function which slows the progression of kidney disease.
  • While Premier Dialysis primarily serves patients receiving peritoneal dialysis, they do also serve a growing number of hemodialysis patients.
  • "Josh and the team at Premier are very much aligned with our vision of the future of kidney disease management," said David Kuraguntla, CEO and co-founder of Alio.

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

Retrieved on: 
Monday, September 11, 2023

MIAMI, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced clinical data from the discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for the 3rd line or greater in the metastatic setting of AR+ER+HER2- breast cancer. Enrollment was discontinued in order to prioritize and focus the clinical development of enobosarm therapy earlier in the treatment sequence, the 2nd line metastatic setting, for AR+ER+HER2- metastatic breast cancer in the Phase 3 ENABLAR-2 (enobosarm +/- abemaciclib CDK 4/6 inhibitor) study. Data reported from the discontinued trial, which is based on an analysis of available data, may not be predictive of the results of larger, later-stage controlled clinical trials.

Key Points: 
  • “The clinical results from the ARTEST study provide promising scientific support and validation for the potential of enobosarm therapy in the ongoing Phase 3 ENABLAR-2 study.
  • The AR+ER+HER2- metastatic breast cancer patients enrolled in the Phase 3 ARTEST study were heavily pretreated.
  • On average, either enobosarm or the standard of care active control in ARTEST was given as 4th line treatment.
  • We are encouraged by these early results, and it appears to be the right decision to move and focus enobosarm’s clinical development earlier to the 2nd line metastatic setting for ER+HER2- metastatic breast cancer patients in the Phase 3 ENABLAR-2 study.”

Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

Retrieved on: 
Thursday, September 7, 2023

CKD is common among mature and senior cats, occurring in about 15-30% of feline patients over 12 years old.

Key Points: 
  • CKD is common among mature and senior cats, occurring in about 15-30% of feline patients over 12 years old.
  • “Chronic kidney disease is not curable, so veterinarians and pet owners are focused on improving quality of life and slowing disease progression in affected cats,” said Dr. Melinda Wood, Specialty Consulting Veterinarian at Elanco.
  • Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
  • Elura has not been evaluated in cats younger than 5 months of age or in breeding, pregnant or lactating cats.